R&D in Vaccines Targeting Neglected Diseases: An Exploratory Case Study Considering Funding for Preventive Tuberculosis Vaccine Development from 2007 to 2014
Table 4
Vaccine candidates in clinical trials.
Candidate
Type
Sponsors/partners
Phase
Ad5 Ag85A
Viral vector
McMaster University (Canada); CanSino (China)
I
ID93 + GLA-SE
Adjuvanted subunit
Infectious Disease Research Institute—IDRI (USA); Aeras (USA)
I
Crucell Ad35/MVA85A
Viral vector
Crucell Holland B.V (Netherlands); University of Oxford (UK); Aeras (USA)
I
Dar-901
M.obuense whole cell
Dartmouth-Hitchcock Medical Center (USA); Aeras (USA)
I
TB/FLU-04L
Viral vector
Research Institute for Biological Safety Problems—RIBSP (Kazakhstan)
I
MVA85A
Viral vector
Oxford University (UK)
I
ChAdOx1-85A/MVA85A
Viral vectors
Oxford University (UK)
I
MVA85A-IMX313
Viral vector
Oxford University (UK); Imaxio (France)
I
MTBVAC
Live genetically attenuated MTB
Tuberculosis Vaccine Institute—TBVI (Netherlands); University of Zaragoza (Spain); Biofabri (Spain)
IIa
VPM 1002
Live rBCG
Max Planck Institute; Vakzine Projekt Management GmbH (Germany); TBVI (Netherlands); Serum Institute of India (India)
IIa
H1 (Ag85B/ESAT) + IC31
Adjuvanted subunit
Statens Serum Institute—SSI (Denmark ); TBVI (Netherlands); Valneva SE (France)
